BLA 761244 · Boehringer Ingelheim Pharmaceuticals INC
Spevigo
Spesolimab-Sbzo · Intravenous · Interleukin-36 Receptor Antagonist
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Sep 1, 2022: To treat generalized pustular psoriasis flares
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 1, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
33
7 Phase 3, 1 recruiting
FAERS reports
403
213 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 8, 2026.
SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. ( 1 )
Mechanism: Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by its ligands (IL-36 α, β and γ) and downstream activation of pro-inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2025 Supplement 4 · Efficacy OrphanLetter
- Mar 18, 2024 Supplement 3 · Efficacy Breakthrough therapyOrphanLabelLetter
- Sep 1, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- SPEVIGO · SPESOLIMAB-SBZO 900MG · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Spesolimab" as an intervention, any sponsor and status, largest first.
- Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis SuppurativaPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05819398 · 209 participants · Start Apr 17, 2023 · Primary completion Aug 1, 2024
Drug: Spesolimab i.v.; Spesolimab s.c. and 2 more · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Los Angeles, California; Sacramento, California · 162 sites in all
- A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar PustulosisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04015518 · 152 participants · Start Jul 31, 2019 · Primary completion Aug 6, 2020
Drug: Spesolimab; Placebo and 4 more · For: Palmoplantar Pustulosis (PPP)
Sites: Birmingham, Alabama; Beverly Hills, California; San Diego, California · 88 sites in all
- Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous StudyActive, not recruiting
LEO PharmaIndustry
NCT03886246 · 131 participants · Start May 29, 2019 · Primary completion Sep 30, 2027
Drug: Spesolimab; Spesolimab · For: Generalized Pustular Psoriasis
Sites: Auburn Hills, Michigan; New York, New York; CABA, Argentina · 58 sites in all
- A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular PsoriasisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04399837 · 123 participants · Start Jun 4, 2020 · Primary completion Nov 23, 2022
Drug: Spesolimab; Placebo · For: Generalized Pustular Psoriasis
Sites: Auburn Hills, Michigan; St Louis, Missouri; CABA, Argentina · 72 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04493424 · 108 participants · Start Sep 4, 2020 · Primary completion Jan 16, 2023
Drug: Spesolimab · For: Palmoplantar Pustulosis
Sites: Birmingham, Alabama; Columbia, Missouri; East Windsor, New Jersey · 66 sites in all
- BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative ColitisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03482635 · 98 participants · Start Mar 27, 2018 · Primary completion May 18, 2020
Drug: Spesolimab; Placebo · For: Colitis, Ulcerative
Sites: Hamden, Connecticut; Miami, Florida; Orlando, Florida · 54 sites in all
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumPivotal-lookingRecruiting
LEO PharmaIndustry
NCT06624670 · 90 participants (planned) · Start Feb 5, 2025 · Primary completion Nov 12, 2027
Drug: Spesolimab; Placebo matching to spesolimab and 2 more · For: Pyoderma Gangrenosum
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 104 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03648541 · 79 participants · Start Oct 29, 2018 · Primary completion May 3, 2023
Drug: Spesolimab · For: Colitis, Ulcerative
Sites: Hamden, Connecticut; Atlanta, Georgia; Chicago, Illinois · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- generalised pustular psoriasis82
- drug ineffective54
- off label use26
- pruritus22
- rash20
- fatigue19
- pustular psoriasis19
- psoriasis16
- pustule15
- maternal exposure during pregnancy14
- asthenia13
- pyrexia13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 13 |
| 2023 | 64 |
| 2024 | 98 |
| 2025 | 115 |
| 2026 | 113 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Spevigo* (Spesolimab-Sbzo)
2024 spending
$4.9M
Beneficiaries
55
185 claims
Per beneficiary
$89,061
$7,736.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $583,545 |
| 2023 | $1,705,416 |
| 2024 | $4,898,328 |
Part B: Spevigo (Spesolimab-Sbzo) · HCPCS J1747
2024 spending
$4.6M
Beneficiaries
47
96 claims
Per beneficiary
$98,343
2024 ASP limit $60.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,732,343 |
| 2024 | $4,622,120 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H, Choon SE, Marrakchi S, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Comparative Study
- Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH, Wu PC, Chiu HY, et al. · Am J Clin Dermatol 2024 · Systematic Review, Comparative Study
- Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- A systematic review of recent randomized controlled trials for palmoplantar pustulosis.
Branyiczky MK, Towheed S, Torres T, et al. · J Dermatolog Treat 2024 · Systematic Review
- Efficacy and Safety of All Monoclonal Antibodies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis.
Cai W, Fu L, Wu Y, et al. · Pharmacoepidemiol Drug Saf 2025 · Systematic Review, Network Meta-Analysis
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.